Today, Bedrocan produces five plant varieties for patient use. Each product is standardised according to pharmaceutical standards with a defined active ingredient composition. This reproducible chemical profile allows doctors to monitor dosage and condition progress like they would with any other treatment.
At Bedrocan we consider scientific research a vital tool to make medicinal cannabis an approved medicine. That’s why we support clinical trials worldwide and offer our services and experience to medicinal cannabis research projects.
Bedrocan products are used by the pharmaceutical industry. Standardised Active Pharmaceutical Ingredients (API) of pharmaceutical quality, in various formats, meet the needs of large and small drug developers.
Tjalling Erkelens explains that measures to curb the spread of the coronavirus do not affect Bedrocan’s medicinal cannabis production. “We can produce for the next few months undisrupted”, he says.
Watch the interview here:
While the coronavirus outbreak and associated security measures are affecting everyone’s lives, we manage to keep our medicinal cannabis production on schedule.
Of course we have taken the necessary measures. Read more.